| Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial M Hallek, K Fischer, G Fingerle-Rowson, AM Fink, R Busch, J Mayer, ... The Lancet 376 (9747), 1164-1174, 2010 | 2377 | 2010 |
| Mutations driving CLL and their evolution in progression and relapse DA Landau, E Tausch, AN Taylor-Weiner, C Stewart, JG Reiter, J Bahlo, ... Nature 526 (7574), 525-530, 2015 | 1131 | 2015 |
| Venetoclax and obinutuzumab in patients with CLL and coexisting conditions K Fischer, O Al-Sawaf, J Bahlo, AM Fink, M Tandon, M Dixon, S Robrecht, ... New England Journal of Medicine 380 (23), 2225-2236, 2019 | 853 | 2019 |
| Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial K Fischer, J Bahlo, AM Fink, V Goede, CD Herling, P Cramer, ... Blood, The Journal of the American Society of Hematology 127 (2), 208-215, 2016 | 794 | 2016 |
| First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10 … B Eichhorst, AM Fink, J Bahlo, R Busch, G Kovacs, C Maurer, E Lange, ... The lancet oncology 17 (7), 928-942, 2016 | 733* | 2016 |
| Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial S Stilgenbauer, A Schnaiter, P Paschka, T Zenz, M Rossi, K Döhner, ... Blood, The Journal of the American Society of Hematology 123 (21), 3247-3254, 2014 | 624 | 2014 |
| Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic … K Fischer, P Cramer, R Busch, S Böttcher, J Bahlo, J Schubert, KH Pflüger, ... J Clin oncol 30 (26), 3209-3216, 2012 | 563 | 2012 |
| Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the … S Böttcher, M Ritgen, K Fischer, S Stilgenbauer, RM Busch, ... J Clin Oncol 30 (9), 980-988, 2012 | 555 | 2012 |
| First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia BF Eichhorst, R Busch, S Stilgenbauer, M Stauch, MA Bergmann, ... Blood, The Journal of the American Society of Hematology 114 (16), 3382-3391, 2009 | 453 | 2009 |
| Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia N Pflug, J Bahlo, TD Shanafelt, BF Eichhorst, MA Bergmann, T Elter, ... Blood, The Journal of the American Society of Hematology 124 (1), 49-62, 2014 | 359 | 2014 |
| Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R)(FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free … M Hallek, G Fingerle-Rowson, AM Fink, R Busch, J Mayer, M Hensel, ... Blood 112 (11), 325, 2008 | 342 | 2008 |
| Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open … O Al-Sawaf, C Zhang, M Tandon, A Sinha, AM Fink, S Robrecht, ... The Lancet Oncology 21 (9), 1188-1200, 2020 | 295 | 2020 |
| Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GINEMA infection program DL Pagano, C Girmenia, L Mele, P Ricci, ME Tosti, A Nosari, M Buelli, ... haematologica 86 (8), 862-870, 2001 | 211 | 2001 |
| Minimal residual disease assessment improves prediction of outcome in patients with chronic lymphocytic leukemia (CLL) who achieve partial response: comprehensive analysis of … G Kovacs, S Robrecht, AM Fink, J Bahlo, P Cramer, J von Tresckow, ... Journal of Clinical Oncology 34 (31), 3758-3765, 2016 | 206 | 2016 |
| First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R)(FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced … M Hallek, G Fingerle-Rowson, AM Fink, R Busch, J Mayer, M Hensel, ... Blood 114 (22), 535, 2009 | 140 | 2009 |
| Venetoclax and obinutuzumab in chronic lymphocytic leukemia K Fischer, O Al-Sawaf, AM Fink, M Dixon, J Bahlo, S Warburton, TJ Kipps, ... Blood, The Journal of the American Society of Hematology 129 (19), 2702-2705, 2017 | 132 | 2017 |
| cyclophosphamide (C), and rituximab (R)(FCR) shows superior efficacy in comparison to bendamustine (B) and rituximab (BR) in previously untreated and physically fit patients … B Eichhorst, AM Fink, R Busch, G Kovacs, C Maurer, E Lange Blood 124 (21), 19, 2014 | 123 | 2014 |
| Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): a multicentre phase II trial of the German CLL Study Group (GCLLSG) K Fischer, S Stilgenbauer, CD Schweighofer, R Busch, J Renschler, ... Blood 112 (11), 330, 2008 | 116 | 2008 |
| Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial P Cramer, J von Tresckow, J Bahlo, S Robrecht, P Langerbeins, ... The Lancet Oncology 19 (9), 1215-1228, 2018 | 113 | 2018 |
| Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax E Tausch, C Schneider, S Robrecht, C Zhang, A Dolnik, J Bloehdorn, ... Blood, The Journal of the American Society of Hematology 135 (26), 2402-2412, 2020 | 112 | 2020 |
Michael HallekUniversity of CologneBestätigte E-Mail-Adresse bei uni-koeln.de
